TG Therapeutics, Inc. Announces Third Quarter 2015 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
TG Therapeutics' (TGTX) Q3 Results Solid; Roth Remains Positive into ASH Conference
November 9, 2015 2:20 PM ESTRoth Capital affirmed its Focus Pick rating and $33 price target on TG Therapeutics (NASDAQ: TGTX) following the company's Q3 report and update issued earlier Monday.
Analyst Joseph Pantginis commented, We believe that TG is entering an intriguing time as we look toward more mature data updates at ASH... More
TG Therapeutics (TGTX) Tops Q3 EPS by 6c
November 9, 2015 7:49 AM ESTTG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.28), $0.06 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $38.1 thousand versus the consensus estimate of $40 thousand.
For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.
... More